Newly released report details Company’s achievements and plans
for sustainable growth
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global
oncology company, released its 2023 Responsible Business &
Sustainability Report highlighting the Company’s strategy, the
progress it has made towards existing goals, and how it intends to
achieve its bold new targets.
This report comes at a time of tremendous growth for BeiGene. In
2023, the Company achieved the milestone of more than 1 million
patients who were treated worldwide with BTK inhibitor BRUKINSA®
(zanubrutinib) and anti-PD-1 antibody TEVIMBRA® (tislelizumab). The
Company is also actively expanding its presence globally, including
in the U.S., where it expects to open a flagship research and
development and manufacturing facility at the Princeton West
Innovation Campus in Hopewell, New Jersey, in July.
“All patients with cancer deserve access to high-quality,
impactful medicines regardless of their location or socioeconomic
status, but many wait years to access, or simply cannot afford,
innovative treatment options. Our founding belief is that there is
a better way to lower these barriers and broaden our reach and
impact, which is why we’ve strategically built our company to bring
our medicines to more people faster and in a more cost-efficient
manner,” said John V. Oyler, Co-Founder, Chairman and CEO at
BeiGene. “Our commitment to innovation extends beyond our labs, and
as a leading global oncology company with an ongoing mission to
being a good corporate citizen, we know we must continue to do
right not only by our patients, colleagues and stakeholders, but
also the communities in which we operate.”
BeiGene’s Responsible Business & Sustainability strategy is
centered around four pillars: Advancing Global Health, Empowering
Our Colleagues, Innovating Sustainably, and Operating Responsibly.
Beginning in 2021, BeiGene committed to setting goals for each of
these pillars and reporting on progress annually.
Key Achievements
BeiGene’s Responsible Business & Sustainability Report
highlights key achievements from 2023, including:
- Improved the percentage of women holding positions of Vice
President and higher from 33% to 38% year over year.
- Established a global health equity strategy.
- Surpassed 20,000 hours of employee volunteerism worldwide.
- Integrated climate risk into our Enterprise Risk Management
process.
- Launched a supplier engagement program, which will help enable
BeiGene to set a Scope 3 target by 2025.
Setting First Quantitative Climate Goal
BeiGene understands that human health and the health of the
planet are intrinsically linked. As a company focused on improving
health and health equity, it is committed to operating in a way
that mitigates environmental impacts.
In 2023, BeiGene announced its first quantitative climate goal
to reduce its Scope 1 and 2 emissions, emissions generated by owned
and operated facilities, by 25% per unit of internally manufactured
commercial product by 2026 from a 2021 base year.
To meet its climate goal, BeiGene is implementing a strategic
roadmap that includes energy efficiency projects and renewable
energy purchases, including installing solar panels on its
manufacturing facilities.
Expanding Access to Patients Worldwide
The BeiGene Foundation was launched in early 2023 as an
independent 501(c)(3) nonprofit organization dedicated to
eliminating barriers to equitable and accessible cancer in
underrepresented communities around the world. In its first year,
the BeiGene Foundation gave a grant to the Max Foundation as a part
of a collaboration between it, the Max Foundation and BeiGene, to
provide access to BRUKINSA for the treatment of adult patients with
chronic lymphocytic leukemia in 29 low- and middle-income countries
over the next three years. This collaboration advances each
organization’s focus on patient access by combining Max’s expertise
and infrastructure with donated product from BeiGene, and a grant
from the BeiGene Foundation.
“We are proud of the progress we’ve made on our priority areas
in just a few short years,” said Christine Riley Miller, Global
Head of Responsible Business & Sustainability at BeiGene. “We
recognize that as BeiGene grows, so does our responsibility to
maximize opportunities for positive change and minimize negative
impacts to our business, society, and the planet. We look forward
to continuing our journey.”
For more information about BeiGene’s Responsible Business &
Sustainability strategy, achievements, and goals, please download a
copy of the report here.
About BeiGene
BeiGene is a global oncology company that is discovering and
developing innovative treatments that are more affordable and
accessible to cancer patients worldwide. With a broad portfolio, we
are expediting development of our diverse pipeline of novel
therapeutics through our internal capabilities and collaborations.
We are committed to radically improving access to medicines for far
more patients who need them. Our growing global team of more than
10,000 colleagues spans five continents, with administrative
offices in Basel, Beijing, and Cambridge, U.S. To learn more about
BeiGene, please visit www.beigene.com and follow us on LinkedIn, X
(formerly known as Twitter) and Facebook.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
and other federal securities laws, including statements regarding
the future growth and global expansion of BeiGene; the ability of
BeiGene to meet the goals set forth in its 2023 Responsible
Business & Sustainability Report; and BeiGene’s plans,
commitments, aspirations, and goals under the heading “About
BeiGene.” Actual results may differ materially from those indicated
in the forward-looking statements as a result of various important
factors, including BeiGene's ability to demonstrate the efficacy
and safety of its drug candidates; the clinical results for its
drug candidates, which may not support further development or
marketing approval; actions of regulatory agencies, which may
affect the initiation, timing and progress of clinical trials and
marketing approval; BeiGene's ability to achieve commercial success
for its marketed medicines and drug candidates, if approved;
BeiGene's ability to obtain and maintain protection of intellectual
property for its medicines and technology; BeiGene's reliance on
third parties to conduct drug development, manufacturing,
commercialization, and other services; BeiGene’s limited experience
in obtaining regulatory approvals and commercializing
pharmaceutical products; BeiGene’s ability to obtain additional
funding for operations and to complete the development of its drug
candidates and achieve and maintain profitability; and those risks
more fully discussed in the section entitled “Risk Factors” in
BeiGene’s most recent annual report on Form 10-K, as well as
discussions of potential risks, uncertainties, and other important
factors in BeiGene's subsequent filings with the U.S. Securities
and Exchange Commission. All information in this press release is
as of the date of this press release, and BeiGene undertakes no
duty to update such information unless required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240426822500/en/
Investor Contact Liza Heapes +1 857-302-5663
ir@beigene.com
Media Contact Kyle Blankenship +1 667-351-5176
media@beigene.com
BeiGene (NASDAQ:BGNE)
Historical Stock Chart
From Apr 2024 to May 2024
BeiGene (NASDAQ:BGNE)
Historical Stock Chart
From May 2023 to May 2024